Analysts Say Novartis To Emerge $1 Billion Richer With New Ranbaxy Ban
This article was originally published in PharmAsia News
Executive Summary
Novartis and its Diovan (valsartan) blood-pressure drug could get another year on the market without a competitive challenge as a result of U.S. FDA action adding a third Ranbaxy Laboratories plant to its ban list.